VivoSeq
Metabolic & Endocrine

Diabetes, Type 2

3

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Diabetes, Type 2 is an early-stage landscape with 3 programs across 4 companies. The most active players are Novo Nordisk, Richmond Pharmacology Limited, Bayer. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

100/100

Completion Rate

71/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novo Nordisk logo

Novo Nordisk

2 programs

Phase 3R

Richmond Pharmacology Limited

1 program

PreclinicalBayer logo

Bayer

1 program

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Moxifloxacin

Bayer

Phase 1
No programs
Phase 2
No programs
Phase 32

Insulin Icodec

Novo Nordisk

Insulin Glargine

Novo Nordisk

Approved
No programs

Analysis

Trial Status

9

clinical trials

Completed5 · 56%
Unknown status1 · 11%
Withdrawn1 · 11%
Terminated1 · 11%
Not yet recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

"An Online Personalised Lifestyle Program With a Virtual AI Lifestyle Coach in Combination With Continues Glucose Monitoring for People With Type 2 Diabetes."
Not yet recruiting·UUniversity of Twente·Preclinical·NCT07661381·160 enrolled
Vitamin D for the Prevention of Diabetes Type 2
Completed·UUniversity of Tromso·Phase 2/3·NCT00685594·511 enrolled
DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2
Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT03361098·65 enrolled
Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women
Completed·RRio de Janeiro State University·Phase 4·NCT01827280·40 enrolled
A Study to Evaluate the Efficacy and Safety of Once-weekly Insulin Icodec When Switching From Daily Basal Insulins Compared to Once-daily Insulin Glargine U100 in Adults With Type 2 Diabetes
Completed·Novo Nordisk logoNovo Nordisk·Phase 3·NCT06340854·412 enrolled
Efficacy and Safety of the Artificial Intelligence-assisted Insulin Dose Adjustment System for Glycaemic Control in Patients With Type 2 Diabetes Mellitus in General Wards: a Multicentre, Single-blind, Randomised Controlled Study
Completed·SShanghai Zhongshan Hospital·Preclinical·NCT06319300·144 enrolled
A Single Centre, Placebo-controlled Study to Evaluate the Combined Effect of Hyperglycaemia and a QTc-prolonging Medication on Cardiac Repolarisation in Male and Female Patients With Insulin Resistant Type 2 Diabetes Mellitus (T2DM)
Terminated·RRichmond Pharmacology Limited·Preclinical·NCT07014735·14 enrolled
Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
Withdrawn·Merck & Co. logoMerck & Co.·Phase 4·NCT01510522
Study of the Efficacy and Tolerance of Oral Treatment With a Total Freeze-dried Culture of Lcr Restituo® Sachets (Lactobacillus Rhamnosus Lcr35®) on Intolerance to Metformin (Diarrhoea) in Patients With Diabetes Type 2
Unknown status·BBiose·Phase 2·NCT02730741·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)